Loss of MYSM1 deubiquitinase catalytic activity protects against MYC-driven B cell lymphoma via tumor intrinsic effects and indirect modulation of antitumor immunity
Preprint
Abstract
Background: MYC is an oncogenic transcription factor that is over-expressed, amplified, or otherwise dysregulated in over 50% of all cancers. This includes over 10% of diffuse large B-cell lymphomas (DLBCL), where MYC translocations are associated with a poor therapy response and inferior prognosis for the patients. However, because MYC lacks ligand-binding or catalytic domains, it is a highly challenging drug target, and there is a wide interest in novel approaches to inhibit MYC oncogenic functions. MYSM1 is a chromatin-binding deubiquitinase (DUB) that promotes gene expression by catalytically removing the histone H2AK119ub epigenetic mark. In recent work, we demonstrated that MYSM1 acts in cooperation with MYC to sustain the expression of oncogenic transcriptional programs in hematopoietic cells, identifying MYSM1 as a potential therapeutic target for MYC-driven malignancies. Results: Here, we show for the first time that the loss of MYSM1 DUB catalytic activity, without the loss of MYSM1 protein expression, is sufficient to protect against MYC-driven lymphoma in murine models. We characterize the impact of MYSM1 loss-of-function on tumor cell physiology and on antitumor immunity, examining the tumor-intrinsic and the immune cell-mediated mechanisms involved in the protection against the disease. Leveraging human cancer genome databases, we provide first evidence linking MYSM1 loss-of-function to reduced fitness of human lymphoma cell lines in culture and to more favorable clinical outcomes in cancer patients. Conclusions: Overall, our studies support pharmacological inhibition of MYSM1 DUB catalytic function as a novel therapeutic strategy for MYC-driven lymphoma and potentially other cancers.Keywords
Funding Information
- The Leukemia & Lymphoma Society of Canada
This publication has 87 references indexed in Scilit:
- Human hematopoietic stem cell vulnerability to ferroptosisCell, 2023
- The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitorsCancer Immunology, Immunotherapy, 2020
- MYSM1 Represses Innate Immunity and Autoimmunity through Suppressing the cGAS-STING PathwayCell Reports, 2020
- Mysm1 expression in the bone marrow niche is not essential for hematopoietic maintenanceExperimental Hematology, 2017
- Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors2016
- An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiationJournal of Allergy and Clinical Immunology, 2015
- Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 ComplexesImmunity, 2015
- H2A-DUBbing the mammalian epigenome: Expanding frontiers for histone H2A deubiquitinating enzymes in cell biology and physiologyThe International Journal of Biochemistry & Cell Biology, 2014
- MYC on the Path to CancerCell, 2012
- T Cell Myc-tabolismImmunity, 2011